1. MDNA132 is an IL-13 Superkine selective to IL-13Rα2 with broad potential for delivery of immunotherapies to the tumor microenvironment. (October 2022) Authors: Sharma, A.; To, M.; Gobeil, P.; Merchant, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗